In the 1960s, pharmaceutical research in Japan was at the cutting edge.
The young Casero brothers, Alessandro, a polyglot and orientalist, and Riccardo, an expert pharmacist, began their story in this country of the Far East. Although Alessandro spoke Japanese perfectly (which was more unique in those days) and Riccardo was very well prepared, it was very difficult to get the local pharmaceutical companies to even meet with them. However, they had great tenacity and an ambitious goal: to bring still unknown, innovative molecules to Italy.
Trip after trip, bow after bow, the Casero brothers managed to win the trust of the most important Japanese groups, and above all to obtain exclusivity for their products.
It was 1969. Farmaka was born.
The import of active ingredients from Japan has been and continues to be one of the pillars of Farmaka. Thanks to this, since the mid-eighties the company has been able to finance a series of important investments in research and innovation and to transform its core business.
Today, Farmaka's products are distributed in more than 30 countries worldwide.
In 2015, the company was acquired by Alessandro Casero jr., son of Riccardo. Humbly inspired by the values of his founders, Alessandro keeps his feet planted firmly on the ground while at the same time looking far ahead, as evidenced by the decision to quadruple investments in research and development for the three-year period from 2018 to 2020.
His management has coincided with a regular increase in turnover, with a growth of over 40% in the last four years.
Riccardo and Alessandro Casero co-founded Farmaka, a company specialized in importing active ingredients from Japan.
Application for the first registration to the, at the time, Ministry of Health.
Italian registration of Clotiazepam (benzodiazepine) and launch of Tienor® and Rizen® as a co-marketing operation.
Italian registration of Midecamicina (macrolide antibiotic) later launched as Midecin®.
Italian registration of Etizolam (benzodiazepine), launched as Depas® and Pasaden®, another co-marketing operation. Italian registration of Promelasi (proteolytic enzyme) and launch of Flaminase® and Altan® specialties.
New investments in R&D, specifically in dermatology and trichology, and patent of HUCP®, hyaluronic acid extracted from human umbilical cord to be used in these therapeutic areas.
Launch of Kevis® (trichological formulations) in Italy, Spain and USA.
Acquisition of a patent for solubilization of Diclofenac (NSAID).
Launch of Kouriles® dermatological formulations in Italy and Spain.
Italian registration of a diclofenac-based mouthwash, launched as Dicloral® and Zeroflog® as a co-marketing operation.
Registration and launch of Diclodent® mouthwash in Portugal.
Registration and launch of Dicloral® mouthwash in China.
Acquisition of a trichogen enzymes patent, namely HSOR (HydroSteroid OxidoReductase).
Farmaka starts developing medical devices in dermatology.
Between 2007 and 2010 registration and launch of Glimbax® and Dixol® mouthwash in Bulgaria, Hungary, Poland, Romania and Slovakia.
Launch of Dermalex® Rosacea and Biodermal® Couperose medical device in Belgium, France, The Netherlands, Scandinavian Countries and UK.
Farmaka is ISO13485 certified.
Launch of ApnibenQ® and Diclomed® mouthwash in South Korea.
Opening of “Farmaka House”, the new headquarters in Milan.
Launch of Dermalex® Acne medical device in Belgium, France, The Netherlands, Scandinavian Countries and UK.
Alessandro Casero Jr., son of Riccardo, obtains 100% of company shares.
Launch of the first and unique medical device for the prevention of most common foot infections, with the name of Excilor® Protector Spray in Belgium, France, Italy, The Netherlands, Portugal, Spain, UK and Hong Kong.
Launch of Kouriles® in China.
Launch of Dermakalm® Rosa Cream in Canada.
Farmaka is GMP certified as importer of active ingredients.
Launch of the first topical hair loss product of the Oenobiol® brand in Belgium, France, Italy, Portugal and Spain.
For the first time, Farmaka starts distributing its brands directly on the Italian market.
Farmaka celebrates an important anniversary, 50 years, in the iconic Castello Sforzesco in Milan, paying homage to Leonardo Da Vinci on the occasion of the 500th anniversary of his death.
Farmaka hosts its international partners in Milan for the first Diclofenac Global Meeting.
Launch of OKNE®, dermo-cosmetic line for acne-prone skin developed and designed for the Italian market by Farmaka.
Launch of Farmaka Mikro-Stop Spray, the first and only film-forming aerosol for the sanitization and protection of the hands.
Launch of Mikro-Stop Spray 50 ml, same formulation in a more practical and convenient format.
Launch of Roxxia® eudermic emulsion in the USA, a specific formulation for seborrheic dermatitis.
Relaunch of the Kouriles® dermocosmetic line with the addition of two new products: Gentle Cleanser, for face and body, and Soothing Spray for irritation and dermatitis on large areas of the body.
If you’re looking for a team of professionals to develop something unique, or if you are interested in distributing one of our formulations, or again if you have a discovery you would like to share, you can contact us here.Contact Us